Inceptionr LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,908 shares of the biotechnology company’s stock, valued at approximately $1,326,000.
A number of other large investors have also recently bought and sold shares of the company. CIBC Asset Management Inc boosted its position in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 86 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after acquiring an additional 100 shares during the last quarter. Manchester Capital Management LLC boosted its position in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. boosted its position in Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 138 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after acquiring an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.
Sarepta Therapeutics Stock Up 4.7 %
SRPT stock opened at $107.67 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $10.28 billion, a price-to-earnings ratio of 86.14 and a beta of 0.75. The business’s fifty day moving average price is $115.12 and its two-hundred day moving average price is $122.01. Sarepta Therapeutics, Inc. has a fifty-two week low of $99.50 and a fifty-two week high of $173.25.
Wall Street Analyst Weigh In
Get Our Latest Analysis on Sarepta Therapeutics
Insiders Place Their Bets
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
- Five stocks we like better than Sarepta Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Buy P&G Now, Before It Sets A New All-Time High
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What is the S&P/TSX Index?
- Is Advanced Micro Devices Stock Slide Over?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.